Online-Only Abstracts  by unknown
Online-Only Abstracts
Characterization of the first report of Mycobacterium timonense infecting an HIV patient in an
Ecuadorian hospital
J. Zurita1,2,3, D. Ortega-Paredes3, M. Mora3, N. Espinel3, H. Parra4, L. Febres5 and C. Zurita-Salinas3
1) Servicio de Microbiologıa y Tuberculosis, Hospital Vozandes, 2) Facultad de Medicina, Pontificia Universidad Catolica del Ecuador, 3) Unidad de Investigaciones
en Biomedicina, Zurita & Zurita Laboratorios, 4) Centro de Investigaciones Microbiologicas, Guayaquil, Ecuador and 5) Servicio de Traumatologıa, Hospital
Vozandes, Quito, Ecuador
Original Submission: 24 March 2014; Revised Submission: 28 April 2014; Accepted: 7 May 2014
Editor: M. Drancourt
Article published online: 11 May 2014
Clin Microbiol Infect 2014; 20: O1113–O1116
10.1111/1469-0691.12675
Abstract
Mycobacterium timonense is a non-tuberculous mycobacteria (NTM) described in southern France in 2009, and to our knowledge, not
reported again as a human pathogen in indexed literature. The aim of this work was to characterize the first clinical isolate of M. timonense
in Ecuador. Time of growth, biochemical tests, thin layer growth test, PCR-RFLP analysis of the hsp65 gene and MALDI-TOF spectra analysis
were not able to identify the species. The species identification was achieved through sequencing of rrs, hsp65 and rpoB genes. The results
highlight the necessity to set up a sequencing method to identify emerging NTM in Ecuadorian clinical facilities.
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Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of
tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21-month study period,
260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was
significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15–48.65;
p 0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of
tigecycline resistance.
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Abstract
We characterized 53 OXA-48-producing Klebsiella pneumoniae (OXA-48-Kp) isolated between 2011 and 2013 in 21 French hospitals. All
the isolates were genotyped using MLST and PFGE and the population structure of the species was determined by a nucleotide-based
analysis of the entire K. pneumoniae MLST database. Most of the OXA-48-Kp isolates also produced CTX-M-15 and remained susceptible to
imipenem and meropenem. The isolates were distributed into 20 STs, of which five were dominant (ST15, ST101, ST147, ST395 and
ST405). All the OXA-48-Kp clustered in the major clade of K. pneumoniae KpI.
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Abstract
The in vitro susceptibility profile to amikacin, linezolid, clarithromycin, imipenem, cefoxitin, clofazimine and tigecycline was established for 67
strains belonging to theMycobacterium abscessus complex. Clofazimine and tigecycline were among the most effective drugs, prompting us to
assess the effect of a clofazimine and tigecycline combination. Synergistic activity was found in 42% of the 19 isolates tested. The clinical
impact of this new drug combination against the M. abscessus complex, as an alternative or sequential medication for the treatment of
drug-resistant strains, remains to be addressed.
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